Efficacy and Safety of Oral Bosentan in Patients With Idiopathic Pulmonary Fibrosis

Phase 2

Completed

• Conditions: Idiopathic Pulmonary Fibrosis
• Interventions: Drug: bosentan; Drug: Placebo

• Registration Number: NCT00071461
• Lead Sponsor: Actelion

Brief Summary

Endothelin-1 (ET-1) is expressed in a variety of pulmonary pathological conditions including pulmonary vascular disease and pulmonary fibrosis.

Bosentan (an oral dual ET-1 receptor antagonist) could delay the progression of idiopathic pulmonary fibrosis (IPF), a condition for which no established treatment is available.

The present trial investigates a possible use of bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO class III and IV, to a new category of patients suffering from IPF.

It was decided to offer Open Label treatment (bosentan) for patients willing to continue in the BUILD 1 study.

Detailed Description

Not available

Study Timeline

• Study Start: 2003-08
• Study First Submitted: 2003-10-23
• Study First Submitted QC: 2003-10-23
• Study First Posted: 2003-10-24
• Primary Completion: 2005-09
• Disposition First Submitted: 2010-02-11
• Disposition First Submitted QC: 2010-02-11
• Disposition First Posted: 2010-02-15
• Study Completion: 2010-05
• Status Verified: 2012-02
• Last Update Submitted: 2012-02-22
• Last Update Posted: 2012-02-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 158

Inclusion Criteria

1. Male or female patients over 18 years of age.

   • Women must be either postmenopausal (i.e., amenorrhea for at least 1 year), or surgically or naturally sterile.
   • Women of childbearing potential must have a negative pre-treatment pregnancy test and use a reliable method of contraception during study treatment and for at least 3 months after study treatment termination.

2. IPF proven diagnosis < 3 years documented according to ATS/ERS international multidisciplinary consensus, with or without surgical (thoracoscopic or open) chest lung biopsy

3. Duration of illness ≥ 3 months.

4. Six-minute walk test distance (limited by dyspnea) ≥ 150 meters and < 500 meters

5. Patients who have signed the informed consent form prior to initiation of any study procedure.

Exclusion Criteria

1. Interstitial lung disease due to conditions other than IPF, including but not limited to radiation, sarcoidosis, hypersensitivity pneumonitis, bronchiolitis obliterans with organizing pneumonia, and cancer.

2. History of clinically significant environmental exposure known to cause pulmonary fibrosis (drugs, asbestos, beryllium, radiation, domestic birds, etc.).

3. Severe concomitant illness limiting life expectancy (< 1 year).

4. FVC ≥ 90% predicted.

5. Severe restrictive lung disease: FVC < 50% predicted or FVC < 1.2 l, or DLco < 30% predicted or residual volume ≥ 120% predicted.

6. Severe obstructive lung disease: FEV1/FVC< 0.65.

7. Documented improvement of patient's condition within 12 months prior to randomization with or without IPF-specific therapy (e.g., corticosteroids, immunosuppressive, cytotoxic or antifibrotic drugs, TNFa blocker, interferon g).

8. Recent pulmonary or upper respiratory track infection (within 4 weeks of randomization).

9. PaO2 < 55 mm Hg (sea level) or 50 mm Hg (altitude) at rest on room air.

10. Echocardiographic evidence of severe pulmonary hypertension (PH): systolic pulmonary pressure ≥ 50 mm Hg or tricuspid regurgitation velocity ≥ 3.2 m/sec (unless severe PH is invalidated by a right heart catheterization). If the pulmonary pressure is not quantifiable, presence of significant right ventricular enlargement or hypertrophy or right ventricular dysfunction.

11. Severe chronic heart failure, e.g., NYHA class III or IV and/or left ventricular ejection fraction < 25%.

12. Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements, e.g., the 6MWT or the PFTs.

    (e.g., angina pectoris, intermittent claudicating, chronic arthritis).

13. Baseline values of liver transaminases, i.e., aspartate aminotransferases (AST) and/or alanine aminotransferases (ALT) > 3 times the upper limit of normal ranges.

14. Moderate to severe hepatic impairment, i.e., Child-Pugh Class B or C.

15. Serum creatinine ≥ 2.5 mg/dl (221 mmol/l) or dialysis.

16. Hemoglobin concentration < 75% the lower limit of normal ranges.

17. Systolic blood pressure < 85 mm Hg.

18. Pregnancy or breast-feeding.

19. Current drug or alcohol dependence.

20. Smoker (≥ 5 cigarettes per day) or former smoker (≥ 5 cigarettes per day) having stopped less than 6 months prior to randomization.

21. Recently started (< 8 weeks from Screening visit) or planned cardio-pulmonary rehabilitation program based on exercise.

22. Treatment with oral corticosteroids (> 15 mg/day prednisone or equivalent), immunosuppressive, cytotoxic or antifibrotic drugs such as TNF alpha blocker, or interferon gamma within 4 weeks of randomization.within 4 weeks of randomization.

23. Treatment with glibenclamide (glyburide), cyclosporine A or tacrolimus within 1 weeks of randomization.

24. Treatment with an endothelin receptor antagonist within 3 months of randomization.

25. Treatment within 3 months of randomization or planned treatment with another investigational drug.

26. Known hypersensitivity to bosentan or any of the excipients.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
1	bosentan	Initial dose: 62.5 mg b.i.d. for 4 weeks. * Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated). * body weight \< 40 kg (90 lb): 62.5 mg b.i.d.
2	Placebo	Initial dose: 62.5 mg b.i.d. for 4 weeks. * Target dose: - body weight \> 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated). * body weight \< 40 kg (90 lb): 62.5 mg b.i.d.

Primary Outcome Measures

Name	Time	Method
Change in 6-minute walk distance	Baseline to End-of-Period 1

Secondary Outcome Measures

Name	Time	Method
Death or treatment failure	Up to End-of-Period 1

Trial Locations

Locations (29)

University of Alabama at Birmingham - Pulmonary Division; 🇺🇸 Birmingham, Alabama, United States

David Geffen School of Medicine at UCLA - Division of Pulmonary and Critical Care Medicine; 🇺🇸 Los Angeles, California, United States

UCSD Medical Center; 🇺🇸 San Diego, California, United States

University of California - Ambulatory Care Center; 🇺🇸 San Francisco, California, United States

National Jewish Medical and Research Center; 🇺🇸 Denver, Colorado, United States

Yale University School of Medicine; 🇺🇸 New Haven, Connecticut, United States

Jackson Memorial Hospital; 🇺🇸 Miami, Florida, United States

University of Iowa Hospitals & Clinics - Department of Internal Medicine; 🇺🇸 Iowa city, Iowa, United States

University of Michigan Health System - Division of Pulmonary & Critical Care Medicine; 🇺🇸 Ann Arbor, Michigan, United States

Mayo Medical School - Mayo Clinic; 🇺🇸 Rochester, Minnesota, United States

Scroll for more (19 remaining)